Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Nanomedicine. 2017 Jun 11;13(7):2131–2139. doi: 10.1016/j.nano.2017.06.004

Figure 1.

Figure 1

NP design and clinical relevance of Ape1 target. A) Schematic of NP components. B) Fold change in survival as compared to median with low and high expression of the DNA repair enzymes Ape1, ATM, and DNA-PK as determined from TCGA portal data. Survival is significantly higher (~50% over median) only in patients with lower than median Ape1 expression. C) Ape1 expression is inversely correlated with survival in patients that received at least 40 Gy as determined from TCGA portal data (RNA seq V2).